In vitro tests indicate that certain varieties of oats may be harmful to patients with coeliac disease

Journal of Gastroenterology and Hepatology (Australia)

Volumn 22, Issue 4, 2007, Pages 528-531

  Silano, Marco ^a,d   Dessì, Mariarita ^b   De Vincenzi, Massimo ^a   Cornell, Hugh ^c  

^a Higher Institute of Health   (Italy)

^b TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^c RMIT UNIVERSITY   (Australia)

^d ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Agglutinating activity; Avenins; Coeliac disease; Gliadin; K562(S) cells; Lysosomes; Oats

Indexed keywords

AVENIN; GLIADIN; PROTEIN;

AGGLUTINATION TEST; ARTICLE; CELIAC DISEASE; CELL STRAIN K 562; CONTROLLED STUDY; DIGESTION; FOOD SAFETY; GLUTEN FREE DIET; HUMAN; HUMAN CELL; IN VITRO STUDY; LYSOSOME; NONHUMAN; OAT; PRIORITY JOURNAL; RAT; RICE; TOXICITY TESTING;

EID: 33947222660     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2006.04512.x     Document Type: Article

References (28)

1. Ciclitira PJ. Committee of the American Gastroenterological Association AGA technical review on celiac sprue. Gastroenterology 2001; 120: 1526-40.
2. Kasarda D, Okita T, Bernardin J et al. Nucleic acid (cDNA) and amino acid sequences of α-type gliadins from wheat. (Triticum Aestivum). Proc. Natl. Acad. Sci. USA 1984; 81: 4712-16.
3. Cornell HJ, Wieser H, Belitz HD. Characterization of the gliadin-derived peptides which are biologically active in coeliac disease. Clin. Chim. Acta 1992; 213: 37-50.
4. Cornell HJ. Wills-Johnson G. Structure-activity relationships in coeliac-toxic gliadin peptides. Amino Acids 2001; 21: 243-53.
5. McLachlan A, Cullis P, Cornell HJ. The use of extended amino acid motifs for focussing on toxic peptides in coeliac disease. J. Biochem. Mol. Biol. Biophys. 2002; 6: 319-24.
6. Thompson T. Do oats belong to a gluten-free diet? J. Am. Diet. Assoc. 1997; 97: 1413-16.
7. Thompson T. Gluten contamination of commercial oat products in the United States. N. Engl. J. Med. 2004; 351: 2021-2.
8. Kupper C. Dietary guidelines and implementation for celiac disease. Gastroenterology 2005; 128: S121-7.
9. Mayer M, Greco L, Troncone R, Auricchio S, Marsh M. Compliance of adolescents with coeliac disease with a gluten-free diet. Gut 1991; 32: 881-5.
10. Sollid LM. Oats intolerance in celiac disease. PLoS. Med. 2004; 1: 1.
11. Granfeldt Y, Hagander B, Bjorck I. Metabolic responses to starch in oat and wheat products. On the importance of food structure, incomplete gelatinization or presence of viscous dietary fibre. Eur. J. Clin. Nutr. 1995; 49: 189-99.
12. Janatuinen EK, Kemppainen TA, Julkunen RJ et al. No harm from five year ingestion of oats in coeliac disease. Gut 2002; 50: 332-5.
13. Lundin KE, Nilsen EM, Scott HG et al. Oats induced villous atrophy in coeliac disease. Gut 2003; 52: 1649-52.
14. De Vincenzi M, Stammati A, Luchetti R, Silano M, Gasbarrini G, Silano V. Structural specificities and significance for coeliac disease of wheat gliadin peptides able to agglutinate or to prevent agglutination of K562 (S) cells. Toxicology 1998; 15: 97-106.
15. Cornell HJ, McLachlan A, Cullis PG. Extraction of cereal prolamins and their toxicity in coeliac disease. J. Biochem. Mol. Biol. Biophys. 2002; 6: 151-8.
16. Auricchio S, de Ritis G, de Vincenzi M et al. Agglutinating activity of gliadin-derived peptides from bread wheat: implications for coeliac disease pathogenesis. Biochem. Biophys. Res. Commun. 1984; 121: 428-33.
17. Cornell HJ, Townley RRW. The effect of gliadin peptides on rat liver lysosomes in relation to pathogenesis of coeliac disease. Clin. Chim. Acta 1973; 49: 181-8.
18. Cornell HJ, Mothes T. The activity of wheat gliadin peptides in 'in vitro' assays for coeliac disease. Biochim. Biophys. Acta 1993; 1181: 169-73.
19. Biagi F, Campanella J, Martucci S et al. A milligram of gluten a day keeps the mucosal recovery away: a case report. Nutr. Rev. 2004; 62: 360-3.
20. Collin P, Thorell L, Kaukinen K, Maki M. The safe threshold for gluten contamination in gluten-free products. Can trace amounts be accepted in the treatment of coeliac disease? Aliment. Pharmacol. Ther. 2004; 19: 1277-83.
21. Green PH, Fleischauer AT, Bhagat G, Goyal R, Jabri B, Neugut AI. Risk of malignancy in patients with celiac disease. Am. J. Med. 2003; 115: 191-5.
22. West J, Logan RF, Smith CJ, Hubbard RB, Card TR. Malignancy and mortality in people with coeliac disease: population based cohort study. BMJ 2004; 329: 716-19.
23. Wieser H, Belitz H-D. Amino acid compositions of avenins separated by reversed-phase high performance liquid chromatography. J. Cerial Sci. 1989; 9: 221-9.
24. Arentz-Hansen H, Fleckenstein B, Molberg O et al. The molecular basis for oat intolerance in patients with celiac disease. Plos Med. 2004; 1: 84-92.
25. Koning F. Celiac disease: caught between a rock and a hard place. Gastroenterology 2005; 129: 1294-301.
26. Kang SK, Lee JY, Chung TW, Kim CH. Overexpression of transglutaminase 2 accelerates the erythroid differentiation of human chronic myelogenous leukemia K562 cell line through PI3K/Akt signaling pathway. FEBS Lett. 2004; 577: 361-6.
27. Maiuri L, Ciacci C, Ricciardelli I et al. Unexpected role of surface transglutaminase type II in celiac disease. Gastroenterology 2005; 129: 1400-13.
28. Alfonso P, Soto C, Albar JP et al. Beta structure motif recognition by anti-gliadin antibodies in coeliac disease. FEBS Lett. 1998; 427: 36-40.